What is IntegReview IRB?
Established in 1999, IntegReview IRB operates as a cornerstone of the clinical trial infrastructure, holding full AAHRPP accreditation. The organization provides comprehensive ethical review services for both industry-sponsored and federally funded research initiatives. Beyond its core IRB functions, the company offers a suite of value-added services, including informed consent development, linguistic translation, site identification, and pre-review consulting. By bridging the gap between complex regulatory requirements and research execution, IntegReview ensures that clinical investigations meet the highest standards of participant protection and scientific integrity.
The company's market position is defined by its longevity and its ability to navigate the evolving regulatory landscape. As clinical trials become increasingly global and data-intensive, the demand for robust, accredited ethical review has intensified. IntegReview leverages its deep domain expertise to support stakeholders in navigating the intricacies of human subject protection, thereby reducing administrative friction and accelerating the research lifecycle.
How much funding has IntegReview IRB raised?
IntegReview IRB has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in IntegReview IRB
PPP
Public-Private Partnership
What's next for IntegReview IRB?
With this late-stage funding, IntegReview is well-positioned to enhance its technological infrastructure and expand its service offerings to meet the growing demands of the pharmaceutical and biotech sectors. The strategic focus will likely center on digitizing the informed consent process and optimizing site identification workflows to improve trial efficiency. By leveraging this capital, the firm aims to reinforce its market leadership, ensuring that its ethical review processes remain agile in the face of emerging clinical research methodologies. The investment serves as a testament to the company's enduring value proposition in a sector where regulatory compliance is non-negotiable.
See full IntegReview IRB company page
